{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:42:06Z","timestamp":1791394926146,"version":"4.3.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Bari Aldo Moro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bispecific antibodies (BiTEs) have transformed the therapeutic landscape of relapsed\/refractory multiple myeloma (RRMM), offering deep and durable responses even in heavily pretreated patients. However, their use carries substantial infectious risk due to immunosuppression, particularly hypogammaglobulinemia, induced by T-cell-redirecting therapy. To define the real-world incidence of grade 3\u20134 infections, we conducted a systematic review and meta-analysis of retrospective studies including RRMM patients treated with BiTEs currently approved for clinical use. Ten studies encompassing 1,373 patients were analysed using a random-effects model of pooled proportions. The overall rate of grade 3\u20134 infections was 0.25 (95% CI, 0.22\u20130.30) after a median follow-up of 8.3 months, with moderate heterogeneity (I\u00b2=52.9%). Subgroup analyses showed comparable pooled event rates for teclistamab\u2014anti-CD3\/BCMA\u2014(0.26; 95% CI, 0.22\u20130.31) and talquetamab\u2014anti-CD3\/GPRC5D\u2014(0.23; 95% CI, 0.14\u20130.33). Meta-regression revealed an inverse association between infection rates and mean number of prior therapy lines (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002) and prior BCMA exposure (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0019), likely because, in real world setting, clinicians select fitter, immunologically stable patients for BiTEs therapy. In summary, approximately one in four RRMM patients receiving BiTEs experiences severe infection. These findings underscore the need for proactive monitoring and standardized preventive measures, including immunoglobulin replacement, prophylaxis, vaccination, to ensure safe, effective integration of BiTEs into routine MM care.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07026-9","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:29:08Z","timestamp":1777264148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis"],"prefix":"10.1007","volume":"105","author":[{"given":"Federico","family":"Spataro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Desantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Dammacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giovanni","family":"Solimando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"6","key":"7026_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111(6):2962\u20132972","journal-title":"Blood"},{"issue":"2","key":"7026_CR2","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK et al (2022) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 9(2):e143\u2013e161","journal-title":"Lancet Haematol"},{"issue":"5","key":"7026_CR3","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD et al (2024) International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol 25(5):e205\u2013e216","journal-title":"Lancet Oncol"},{"issue":"6","key":"7026_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ et al (2022) Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 387(6):495\u2013505","journal-title":"N Engl J Med"},{"key":"7026_CR5","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29:2259\u20132267","journal-title":"Nat Med"},{"key":"7026_CR6","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG et al (2022) Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med 387:2232\u20132244","journal-title":"N Engl J Med"},{"key":"7026_CR7","doi-asserted-by":"publisher","first-page":"1098326","DOI":"10.3389\/fonc.2023.1098326","volume":"13","author":"S Jolles","year":"2023","unstructured":"Jolles S, Giralt S, Kerre T, Lazarus HM, Mustafa SS, Ria R, Vinh DC (2023) Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review. Front Oncol 13:1098326","journal-title":"Front Oncol"},{"key":"7026_CR8","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ\u00a0372:n71","DOI":"10.1136\/bmj.n71"},{"key":"7026_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z et al (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210","journal-title":"Syst Rev"},{"key":"7026_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed) 112:90\u201392","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"7026_CR11","unstructured":"R: A Language and Environment for Statistical Computing (Version 4.3.1). R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org"},{"issue":"5","key":"7026_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/09622802241231496","volume":"33","author":"Y Wang","year":"2024","unstructured":"Wang Y, DelRocco N, Lin L (2024) Comparisons of various estimates of the I2 statistic for quantifying between-study heterogeneity in meta-analysis. Stat Methods Med Res 33(5):745\u2013764","journal-title":"Stat Methods Med Res"},{"key":"7026_CR13","unstructured":"Moga C, Guo B, Schopflocher D et al (2012) Development of a quality appraisal tool for case series studies using a modified Delphi Technique. Institute of Health Economics. https:\/\/ihe.ca\/document\/ihe-quality-appraisal-checklist-for-case-series-studies-with-instructions-for-use\/"},{"issue":"7109","key":"7026_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"key":"7026_CR15","unstructured":"Schunemann H, Bro\u017cek J, Guyatt G et al (2013) GRADE handbook. Grading of recommendations assessment, development and evaluation. GRADE Working Group. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"7026_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"issue":"5","key":"7026_CR17","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41375-025-02552-3","volume":"39","author":"H Mian","year":"2025","unstructured":"Mian H, Martin TG, Pond GR et al (2025) Outcomes of frailty subgroups of older adults (age\u2009\u2265\u200970) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis. Leukemia 39(5):1252\u20131255","journal-title":"Leukemia"},{"issue":"8","key":"7026_CR18","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1007\/s00277-025-06529-1","volume":"104","author":"M Stork","year":"2025","unstructured":"Stork M, Radocha J, Mihalyova J et al (2025) De-escalated Teclistamab dosing in relapsed\/refractory multiple myeloma: Czech myeloma group real-world evidence analysis. Ann Hematol 104(8):4141\u20134147","journal-title":"Ann Hematol"},{"issue":"3","key":"7026_CR19","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3324\/haematol.2023.283590","volume":"109","author":"L Hammons","year":"2024","unstructured":"Hammons L, Szabo A, Janardan A et al (2024) The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica 109(3):906\u2013914","journal-title":"Haematologica"},{"key":"7026_CR20","doi-asserted-by":"crossref","unstructured":"Cani L, Scott SA, Roberts D et al (2025) Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience. Haematologica 111(2):656\u2013664","DOI":"10.3324\/haematol.2025.288187"},{"issue":"1","key":"7026_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N et al (2024) Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J 14(1):35","journal-title":"Blood Cancer J"},{"issue":"2","key":"7026_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, Einsele H, Faltin J, Frenking J, Gezer D, Goldman-Mazur S et al (2024) Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia 38(2):365\u2013371","journal-title":"Leukemia"},{"key":"7026_CR23","doi-asserted-by":"crossref","unstructured":"Razzo BM, Midha S, Portuguese AJ et al (2025) Real-world experience with teclistamab for relapsed\/ refractory multiple myeloma from the U.S. Myeloma Immunotherapy Consortium. Blood Cancer Discov 6(6):561\u2013571","DOI":"10.1158\/2643-3230.BCD-24-0354"},{"issue":"1","key":"7026_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","volume":"15","author":"CR Tan","year":"2025","unstructured":"Tan CR, Asoori S, Huang CY et al (2025) Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J 15(1):53","journal-title":"Blood Cancer J"},{"key":"7026_CR25","doi-asserted-by":"publisher","unstructured":"Yi JH, Lee JH, Jung SH et al (2025) Real-world efficacy and safety of teclistamab for patients with relapsed or refractory multiple myeloma: nationwide retrospective analysis of the named patient program in Korea. Cancer Res Treat Epub ahead of print. https:\/\/doi.org\/10.4143\/crt.2025.399","DOI":"10.4143\/crt.2025.399"},{"key":"7026_CR26","doi-asserted-by":"publisher","first-page":"e70114","DOI":"10.1002\/hem3.70114","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking JH, Riedhammer C, Teipel R et al (2025) A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma. Hemasphere 9:e70114","journal-title":"Hemasphere"},{"key":"7026_CR27","doi-asserted-by":"publisher","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"AG Solimando","year":"2022","unstructured":"Solimando AG, Malerba E, Leone P, Prete M, Terragna C, Cavo M, Racanelli V (2022) Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche. Front Oncol 12:973836","journal-title":"Front Oncol"},{"key":"7026_CR28","doi-asserted-by":"publisher","first-page":"1348955","DOI":"10.3389\/fimmu.2024.1348955","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao A, Zhu J, Niu T (2024) Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials. Front Immunol 15:1348955","journal-title":"Front Immunol"},{"key":"7026_CR29","doi-asserted-by":"crossref","unstructured":"Vandenboom H, Akhtar O, Szabo A et al (2025) Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis. Haematologica 111(2):745\u2013750","DOI":"10.3324\/haematol.2025.288174"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07026-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:46:32Z","timestamp":1781649992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07026-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["7026"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07026-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.E. received honoraria for Bristol-Myers-Squibb, Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis, Roche, Research Funding (BMS\/Celgene, Janssen, Sanofi; GSK, Amgen) Consultancy (Amgen, BMS, Celgene, Janssen, GSK, Novartis, Roche, Sanofi, Takeda); A.V. received speaker honorariums from Pfizer, Sanofi, Bristol Myers Squibb, Takeda, Janssen Cilag, AstraZeneca, Menarini, and Amgen; R.R. has served as a speaker or consultant for Amgen, BMS-Celgene, CSL Behring, Janssen Cilag, Octapharma, Pfizer, Sanofi, Takeda; A.G.S. has received speaker honorariums from Sanofi, Amgen, and AstraZeneca. He has also participated on advisory boards for Pfizer and Menarini. He received travel support for educational purposes from Janssen Cilag. These potential conflicts of interest do not imply bias or influence on the authors\u2019 opinions or actions. The authors are aware of the importance of transparency in the scientific field and are committed to defending their integrity and the trust in them within the scientific community.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}